PDS Biotechnology Q3 2026 net loss narrows to $7.6M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
PDS Biotechnology Corp. (PDSB) reported a net loss of $7.6 million in the third quarter and $24.7 million for the first nine months of 2026, while prioritizing development of PDS0301. Nine-month net loss narrowed from $26.9 million a year earlier, and net cash used in operations was $15.4 million versus $24.0 million. Cash and cash equivalents were $15.2 million at September 30, 2026. The company has no product revenue and expects operating losses to continue.
In August, PDSB announced it would cease internal investment in PDS0101, discontinued the VERSATILE-003 Phase 3 trial and said it would seek a partner or other externally funded opportunity for the program. The September private-placement initial closing raised approximately $11.3 million gross; a further $11 million investment is contingent on submission of a PDS0301 Phase 3 protocol and satisfaction or waiver of closing conditions. PDSB repaid its promissory note for approximately $4.6 million on September 14, 2026.
On November 9, 2026, NantWorks exercised warrants covering 17,699,115 shares at $0.22 per share. PDSB received approximately $3.9 million gross and issued pre-funded warrants for the portion that otherwise would have exceeded the 19.9% beneficial ownership limitation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month net loss narrowed 8% year over year.
Negative
- Major pointVERSATILE-003 Phase 3 trial discontinued in August 2026.
Filing Explained
By September 30, 2026, PDSB had 104.2 million common shares outstanding, versus 54.9 million at year-end, after 31.9 million shares were sold through the ATM.
Form 10-Q is the company’s unaudited quarterly report, and this filing records completed share issuance through its at-the-market program and September private placement. By
The September placement issued 16,502,870 common shares and included pre-funded warrants for up to 23,498,156 shares and common warrants for up to 20,000,514 shares. The pre-funded warrants have a
Key Figures
Key Terms
immunocytokine medical
tumor microenvironment medical
at-the-market offering financial
pre-funded warrants financial
beneficial ownership limitation financial
contingent milestone closing financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were PDSB's losses in the third quarter and first nine months of 2026?
Why did PDSB discontinue the VERSATILE-003 trial?
How much did PDSB raise in its September 2026 private placement?
How much did PDSB receive when NantWorks exercised its warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| | ||
| (Exact name of registrant as specified in its charter) |
| | | |
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |
| | ||
| (Address of principal executive offices) |
| ( | ||
| (Registrant’s telephone number) |
|
(Former name, former address and former fiscal year, if changed since last report)
|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| | | The |
| Large accelerated filer ☐ | Accelerated filer ☐ | | Smaller Reporting Company |
| Emerging growth company |
|
Page
|
|||
|
Part I — Financial Information
|
|||
|
Item 1.
|
Financial Statements (Unaudited):
|
||
|
Condensed Consolidated Balance Sheets
|
3 | ||
|
Condensed Consolidated Statements of Operations and Comprehensive Loss
|
4
|
||
|
Condensed Consolidated Statements of Changes in Stockholders’ Equity
|
5
|
||
|
Condensed Consolidated Statements of Cash Flows
|
6
|
||
|
Notes to Condensed Consolidated Financial Statements
|
7
|
||
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
19 | |
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
32 | |
|
Item 4.
|
Controls and Procedures
|
32 | |
|
Part II — Other Information
|
33 | ||
|
Item 1.
|
Legal Proceedings
|
33 | |
|
Item 1A.
|
Risk Factors
|
33 | |
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
52 | |
|
Item 3.
|
Defaults Upon Senior Securities
|
52 | |
|
Item 4.
|
Mine Safety Disclosures
|
52 | |
|
Item 5.
|
Other Information
|
52 | |
|
Item 6.
|
Exhibits
|
52 | |
|
EXHIBIT INDEX
|
53 | ||
|
SIGNATURES
|
54 | ||
|
PART 1.
|
FINANCIAL INFORMATION
|
|
ITEM 1.
|
FINANCIAL STATEMENTS
|
|
September 30, 2026
|
December 31, 2025
|
|||||||
|
ASSETS
|
(unaudited)
|
|||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Prepaid expenses and other assets
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Noncurrent assets:
|
||||||||
|
Prepaid expenses
|
|
|
||||||
|
Property and equipment, net
|
|
|
||||||
|
Financing lease right-to-use assets
|
|
|
||||||
|
Total assets
|
$
|
|
$
|
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
|
$
|
|
||||
|
Accrued expenses
|
|
|
||||||
|
Current portion of debt
|
|
|
||||||
|
Financing lease obligation-short term
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
Noncurrent liabilities:
|
||||||||
|
Debt, net of debt discount
|
|
|
||||||
|
Financing lease obligation-long term
|
|
|
||||||
|
Total liabilities
|
$
|
|
$
|
|
||||
|
Commitments and contingencies (Note 9)
|
||||||||
|
STOCKHOLDERS’ EQUITY
|
||||||||
| Common stock, $ |
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
|
Accumulated deficit
|
( |
)
|
( |
)
|
||||
|
Total stockholders’ equity
|
|
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
||||
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025 | |||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development expenses
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
General and administrative expenses
|
|
|
|
|
||||||||||||
|
Total operating expenses
|
|
|
|
|
||||||||||||
|
Loss from operations
|
( |
)
|
( |
)
|
( |
)
|
( |
)
|
||||||||
|
Interest income (expense), net
|
||||||||||||||||
|
Interest income
|
|
|
|
|
||||||||||||
|
Interest expense
|
( |
)
|
( |
)
|
( |
)
|
( |
)
|
||||||||
|
Interest expense, net
|
( |
)
|
( |
)
|
( |
)
|
( |
)
|
||||||||
|
Loss before income taxes
|
( |
)
|
( |
)
|
( |
)
|
( |
)
|
||||||||
|
Benefit from income taxes
|
|
|
|
|
||||||||||||
|
Net loss and comprehensive loss
|
( |
)
|
( |
)
|
( |
)
|
( |
)
|
||||||||
|
Per share information:
|
||||||||||||||||
|
Net loss per share, basic and diluted
|
$
|
( |
)
|
$
|
( |
)
|
$
|
( |
)
|
$
|
( |
)
|
||||
|
Weighted average common shares outstanding, basic, and diluted
|
|
|
|
|
||||||||||||
|
Common Stock
|
Additional
|
Accumulated
|
||||||||||||||||||
|
Shares Issued
|
Amount
|
Paid-in Capital
|
Deficit
|
Total Equity
|
||||||||||||||||
|
January 1, 2025
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
|
Stock-based compensation expense
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock for consulting agreement
|
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock from at-the-market program, net
|
|
|
|
|
|
|||||||||||||||
|
Issuances of common stock, net of issuance costs
|
|
|
|
|
|
|||||||||||||||
|
Issuance of pre-funded warrants
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of warrants
|
-
|
|
|
|
|
|||||||||||||||
|
Exercise of pre-funded warrants
|
|
|
( |
)
|
|
|
||||||||||||||
|
Net loss
|
-
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance - March 31, 2025
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
|
Stock-based compensation expense
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock from at-the-market program, net
|
|
|
|
|
|
|||||||||||||||
|
Issuances of common stock, net of issuance costs
|
|
|
|
|
|
|||||||||||||||
|
Issuance of warrants
|
-
|
|
|
|
|
|||||||||||||||
|
Exercise of pre-funded warrants
|
|
|
( |
)
|
|
|
||||||||||||||
|
Net loss
|
-
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance - June 30 , 2025
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
|
Stock-based compensation expense
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock from at-the-market program, net
|
|
|
|
|
|
|||||||||||||||
|
Net loss
|
-
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance - September 30, 2025
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
|
Common Stock
|
Additional
|
Accumulated
|
||||||||||||||||||
|
Shares Issued
|
Amount
|
Paid-in Capital
|
Deficit
|
Total Equity
|
||||||||||||||||
|
January 1, 2026
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
|
Stock-based compensation expense
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock for consulting agreement
|
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock from at-the-market program, net
|
|
|
|
|
|
|||||||||||||||
|
Issuances of common stock, net of issuance costs
|
|
|
|
|
|
|||||||||||||||
|
Issuance of pre-funded warrants
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of warrants
|
-
|
|
|
|
|
|||||||||||||||
|
Exercise of pre-funded warrants
|
|
|
|
|
|
|||||||||||||||
|
Net loss
|
-
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance - March 31, 2026
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
|
Stock-based compensation expense
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock from at-the-market program, net
|
|
|
|
|
|
|||||||||||||||
|
Issuances of common stock, net of issuance costs
|
|
|
|
|
|
|||||||||||||||
|
Issuance of warrants
|
-
|
|
|
|
|
|||||||||||||||
|
Exercise of pre-funded warrants
|
|
|
|
|
|
|||||||||||||||
|
Net loss
|
-
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance - June 30 , 2026
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
( |
)
|
|||||||||
|
Stock-based compensation expense
|
-
|
|
|
|
|
|||||||||||||||
|
Issuance of common stock from at-the-market program, net
|
|
|
|
|
|
|||||||||||||||
|
Issuances of common stock, net of issuance costs
|
|
|
|
|
|
|||||||||||||||
| Issuance of pre-funded warrants |
-
|
|
|
|
||||||||||||||||
| Issuance of common stock warrants |
-
|
|
|
|
||||||||||||||||
| Issuance of contingent milestone commitment |
-
|
|
|
|
||||||||||||||||
|
Issuance of warrants - adjustment
|
-
|
|
|
|
|
|||||||||||||||
|
Net loss
|
-
|
|
|
( |
)
|
( |
)
|
|||||||||||||
|
Balance - September 30, 2026
|
|
$
|
|
$
|
|
$
|
( |
)
|
$
|
|
||||||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
( |
)
|
$
|
( |
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Stock-based compensation expense
|
|
|
||||||
|
Issuance of shares in consulting agreements
|
|
|
||||||
|
Amortization of debt discount
|
|
|
||||||
|
Loss on retirement of debt
|
|
|
||||||
|
Depreciation expense
|
|
|
||||||
|
Finance lease depreciation expense
|
|
|
||||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses and other assets
|
|
( |
)
|
|||||
|
Accounts payable
|
( |
)
|
|
|||||
|
Accrued expenses
|
|
( |
)
|
|||||
|
Net cash used in operating activities
|
( |
)
|
( |
)
|
||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from exercise of pre-funded warrants
|
|
|
||||||
|
Proceeds from issuance of warrants
|
|
|
||||||
|
Payments of finance lease obligations
|
( |
)
|
( |
)
|
||||
|
Loan principal payment
|
( |
)
|
( |
)
|
||||
|
Loan repayment
|
( |
)
|
( |
)
|
||||
|
Net proceeds from issuance of debt
|
|
|
||||||
|
Loan repayment
|
( |
)
|
|
|||||
|
Proceeds from issuance of common stock from at-the-market program, net of issuance costs
|
|
|
||||||
|
Proceeds from issuance of common stock, net of issuance costs
|
|
|
||||||
|
Proceeds from issuance of pre-funded warrants
|
|
|
||||||
|
Proceeds from issuance of common stock warrants
|
|
|
||||||
|
Proceeds from allocation to contingent milestone commitment
|
|
|
||||||
|
Net cash provided by financing activities
|
|
|
||||||
|
Net decrease in cash and cash equivalents
|
( |
)
|
( |
)
|
||||
|
Cash and cash equivalents at beginning of period
|
|
|
||||||
|
Cash and cash equivalents at the end of period
|
$
|
|
$
|
|
||||
|
Supplemental information of cash and non-cash transactions:
|
||||||||
|
Cash paid for interest
|
$
|
|
$
|
|
||||
| (A) | Unaudited interim financial statements: |
| (B) | Use of estimates: |
| (C) | Significant risks and uncertainties: |
| (D) | Cash equivalents and concentration of cash balance: |
| (E) | Research and development: |
| (F) | Patent costs: |
| (G) | Stock-based compensation: |
| (H) | Net loss per common share: |
|
As of September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Stock options to purchase common stock
|
|
|
||||||
|
Performance-based restricted stock units
|
|
|
||||||
|
Warrants to purchase common stock
|
|
|
||||||
|
Total
|
|
|
||||||
| (I) | Income taxes: |
| (J) | Convertible debentures and embedded derivative evaluation: |
| (K) | Warrants to acquire common stock: |
| (L) | Fair value of financial instruments: |
| ● |
Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial
instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
|
| ● |
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active
markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies.
|
| ● |
Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques
and at least one significant model assumption or input is unobservable.
|
| (M) | Leases: |
| (N) | New accounting standards: |
|
Fair Value Measurements at Reporting Date Using
|
||||||||||||||||
|
Total
|
Quoted Prices in
Active Markets
(Level 1)
|
Quoted Prices in
Inactive Markets
(Level 2)
|
Significant
Unobservable Inputs
(Level 3)
|
|||||||||||||
|
As of September 30, 2026: (unaudited)
|
||||||||||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
As of December 31, 2025
|
||||||||||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
As of September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Cash paid for finance lease liabilities
|
$
|
|
$
|
|
||||
|
Year ended December 31,
|
||||
|
2026
|
$
|
|
||
|
2027 and after
|
|
|||
|
Total future minimum lease payments
|
|
|||
|
Less imputed interest
|
( |
)
|
||
|
Remaining lease liability
|
$
|
|
||
|
As of
September 30, 2026
|
As of
December 31, 2025
|
|||||||
|
Accrued research and development
|
$
|
|
$
|
|
||||
|
Accrued professional fees
|
|
|
||||||
|
Accrued compensation
|
|
|
||||||
|
Accrued rent
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
||||
|
Three Months Ended
September 30,
|
Nine Months ended
September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Stock-Based Compensation
|
||||||||||||||||
|
Research and development
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
General and administrative
|
|
|
|
|
||||||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Number
of Shares
|
Weighted Average
Exercise Price
|
|||||||
|
Options outstanding at December 31, 2025
|
|
$
|
|
|||||
|
Granted
|
|
|
||||||
|
Exercised
|
|
|
||||||
|
Forfeited
|
( |
)
|
|
|||||
|
Expired
|
( |
)
|
|
|||||
|
Options outstanding at September 30, 2026
|
|
$
|
|
|||||
|
Vested and expected to vest at September30, 2026
|
|
$
|
|
|||||
|
Exercisable at September 30, 2026
|
|
$
|
|
|||||
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Segment expenses
|
||||||||||||||||
|
Salaries and Benefits
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Professional fees
|
|
|
|
|
||||||||||||
|
General administrative expenses
|
|
|
|
|
||||||||||||
|
Clinical development expenses
|
|
|
|
|
||||||||||||
|
Other development expenses
|
|
|
|
|
||||||||||||
|
Total operating and segment expenses
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Interest income
|
|
|
|
|
||||||||||||
|
Interest expense
|
( |
)
|
( |
)
|
( |
)
|
( |
)
|
||||||||
|
Benefit from income taxes
|
|
|
|
|
||||||||||||
|
Segment and consolidated net loss
|
$
|
( |
)
|
$
|
( |
)
|
$
|
( |
)
|
$
|
( |
)
|
||||
| ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
| ● |
the Company’s recent strategic refocus to prioritize the development of PDS0301 and to discontinue the VERSATILE-003 Phase 3 clinical trial of PDS0101 may not achieve the anticipated benefits and involves
significant risks and uncertainties;
|
| ● |
the Company’s ability to protect its intellectual rights;
|
| ● |
the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings;
|
| ● |
the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its clinical and product candidates, and the risks that raising such additional
capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or clinical and product candidates;
|
| ● |
the Company’s limited operating history in the current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful
implementation of such business plan;
|
| ● |
the timing for the Company or its partners to initiate the planned clinical trials for PDS0301 (formerly PDS01ADC);
|
| ● |
the Company’s ability to successfully secure partnership(s) for the further development of its PDS0101 program;
|
| ● |
the Company may not be able to identify, negotiate, or consummate strategic partnerships or other externally funded opportunities for the continued development of PDS0101, and any such partnerships may not be
on favorable terms;
|
| ● |
the Company may expend its limited resources to pursue PDS0301 and fail to capitalize on other product candidates or indications that may be more profitable or for which there is a greater likelihood of
success;
|
| ● |
the discontinuation of the VERSATILE-003 Phase 3 trial and the Company’s limited cash resources may further impact the Company’s ability to continue as a going concern;
|
| ● |
the successful implementation of the Company’s research and development programs and collaborations, including any collaboration trials concerning the Company’s PDS0301, Versamune® and Infectimune® based
clinical and product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s clinical and product
candidates;
|
| ● |
the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current clinical candidates, including statements regarding the timing of initiation,
pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and
data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials;
|
| ● |
expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of the Company’s clinical and product candidates;
|
| ● |
any Company statements about its understanding of clinical and product candidates’ mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and
any collaboration trials; the acceptance by the market of the Company’s clinical and product candidates, if approved;
|
| ● |
the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s clinical and product
candidates; and
|
| ● |
other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations
arising from or related to those listed under Part II, Item 1A. Risk Factors.
|
| ● |
A Phase 2 trial evaluating PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for subjects with metastatic colorectal cancer, intrahepatic cholangiocarcinoma, or metastatic adrenocortical carcinoma (in
progress)
|
| ● |
A Phase 2 trial evaluating ICI naïve and resistant patients with HPV-positive malignancies treated with PDS0301, PDS0101 and bintrafusp alfa (completed and published in JAMA Oncology 2025)
|
| ● |
A Phase 2 trial evaluating T-cell clonality after stereotactic body radiation therapy alone and in combination with the immunocytokine PDS0301 in localized high and intermediate risk prostate cancer treated with androgen deprivation
therapy (in progress)
|
| ● |
A Phase 1/2 trial evaluating PDS0301 in combination with enzalutamide vs enzalutamide in adults with biochemically recurrent prostate cancer (in progress)
|
| ● |
A Phase 1/2 trial evaluating PDS0301 in combination with docetaxel in adults with metastatic castration sensitive and castration resistant prostate cancer (in progress)
|
| ● |
A Phase 1/2 trial evaluating PDS0301 going forward as a monotherapy in advanced kaposi sarcoma (in progress)
|
| ● |
A Phase 1/2 trial evaluating PDS0301 in combination with a histone deacetylase (HDAC) inhibitor in ICI-resistant MUC1-positive colon and bladder cancers among others
|
| ● |
Decrease in PSA levels was seen in all patients at all three tested doses of PDS0301 and 61% of patients had at least a 60% decrease in PSA levels.
|
| ● |
All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.
|
| ● |
Administration of the combination was associated with decreases in T reg cells and increases in activated natural killer (NK) cells, memory CD8 T cells, proliferating CD4 and CD8 T cells and cytokines INF-γ and Interleukin 10 (IL-10).
|
| ● |
The changes in immune responses with the combination were independent of the PDS0301 dose.
|
| ● |
Objective response rate by RECIST v1.1: 77.8% (7/9) at six months; in the parallel trial without PDS0301, the ORR was 35% (7/20)
|
| ● |
24-month survival rate: Approximately 80%; in the parallel study without PDS0301, the 2-year survival rate was approximately 40%
|
| ● |
Extrahepatic progression-free survival (PFS): median not reached at minimum follow-up of 13.1 months; in the parallel trial without PDS0301, the PFS was 8.1 months
|
| ● |
Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone.
|
| ● |
Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels.
|
| ● |
A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)
|
| ● |
Confirmed and unconfirmed objective response rate is 41.2% (14/34 patients), which is identical to the preliminary response rate data previously reported by us at ASCO 2022 (7/17 patients). To date these responses have been confirmed in
nine of the 34 patients (26.5%), including one complete response.
|
| ● |
15/34 patients (44.1%) had stable disease.
|
| ● |
9/34 patients (26.5%) had progressive disease.
|
| ● |
4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.
|
| ● |
24-month overall survival (OS) rate is 74%; published 24-month survival rate of less than 30% for approved ICI.
|
| ● |
12-month OS rate is 80%; published results of 30-50% with approved ICIs.
|
| ● |
Tumor shrinkage seen in 60% (31/52) of patients.
|
| ● |
Confirmed overall response rate ORR is 27% (14/52) to date.
|
| ● |
Median progression-free survival (PFS) is 8.1 months to date; published results of 2-3 months PFS with approved ICIs.
|
| ● |
13% (8/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and 0% (0/62) experienced Grade 4 or 5 TRAE; published results report 13-17% Grade 3-5 TRAE with approved ICI monotherapy.
|
| ● |
60% (33/55) of patients have CPS score of 1-19 (who generally have a weaker response to Keytruda®), and 40% (22/55) have CPS score >20 (who generally have a higher response to Keytruda®).
|
| ● |
The 12-month OS rate is 56%. The published median 12-month OS rate is 17% with no salvage chemotherapy following tumor progression on ICI (ICI Resistant).
|
| ● |
0% (0/21) confirmed ORR suggests that PDS0101’s impact on survival does not appear to be dependent on tumor shrinkage.
|
| ● |
4% (1/25) of patients experienced Grade 3 TRAE and 0% (0/21) patients experienced Grade 4 and 5 TRAE.
|
| ● |
Median overall survival of 30 months; published results for ICIs are 7-18 months.
|
| ● |
Confirmed overall response rate ORR of 34% (18/53) to date; published results for comparable patients receiving treatment with ICIs are less than 20%.
|
| ● |
Confirmed complete responses, partial responses and stable disease according to RECIST v1.1 were seen in 75.5% of patients.
|
| ● |
Median progression-free survival (PFS) of 6.3 months to date; published results of 2-3 months PFS with approved ICIs.
|
| ● |
The combination of PDS0101 and Keytruda® appeared to be well tolerated with 11% (7/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and 2% (1/62) experienced Grade 4 or 5 TRAE; published results report 13-17%
Grade 3-5 TRAE with approved ICI monotherapy.
|
| ● |
60% (32/53) of patients had CPS score of 1-19 (who generally have a weaker response to Keytruda®), and 40% (21/53) have CPS score >20 (who generally have a higher response to Keytruda®).
|
| ● |
Median Overall Survival of 30 months, consistent with data presented our key opinion leader event in May of 2024, which was based on a data cut as of November 30, 2023.
|
| ● |
27 of the censored patients remained alive and were awaiting their next clinical assessment, 6 censored patients had withdrawn consent for further follow-up, and 2 patients had been lost to follow-up, and 18 patients had died.
|
| ● |
The lower limit of the 95% confidence interval is 19.7 months, and the upper limit is not yet estimable, as the majority of patients continue to be followed for survival.
|
| ● |
Median Overall Survival (mOS) was 30 months with a lower 95% confidence interval of 19.7 months; Published mOS for pembrolizumab is 12-18 months
|
| ● |
Objective Response Rate (ORR) of 36% (19/53); Published ORR for pembrolizumab is 19-25%
|
| ● |
Disease Control Rate (DCR) is 77% (41/53)
|
| ● |
21% (11/53) of patients had deep tumor responses and shrinkage of 90-100%
|
| ● |
9% (5/53) of patients had a complete response
|
| ● |
Treatment-related adverse events of Grade ≥3 were seen in 9 patients (Grade 3, n=8 and Grade 4, n=1)
|
| ● |
The median overall survival (mOS) is 39.3 months in patients with CPS ≥ 1. The lower limit of the 95% confidence interval is 23.9 months, and the upper limit is not yet estimable.
|
| ● |
9 of the 17 patients had completed a Day 170 post-treatment positron emission tomography, computed tomography (PET CT) scan to assess the status of the cancer. This included 78% (7/9) of treated patients with
advanced cervical cancer (FIGO stage III or IV).
|
| ● |
100% (9/9) of patients treated with the combination of PDS0101 and CRT had an objective response.
|
| ● |
89% (8/9) of patients treated with the combination of PDS0101 and CRT demonstrated a complete response (CR) on Day 170 by PET CT. One patient who received 3 of the 5 scheduled doses of PDS0101 showed signs of
residual disease. One patient who had a CR died from an event unrelated to either their underlying disease or treatment.
|
| ● |
1-year disease-free survival and 1-year overall survival of 89% (8/9) in patients treated with the combination of PDS0101 and CRT.
|
| ● |
As previously reported, data confirmed PDS0101 treatment activates HPV16-specific CD8 T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells
generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8 T cells are important mediators of antigen-specific immunity.
|
| ● |
The data affirms that PDS0101 activates Type 1 interferon pathway in humans, mimicking the mechanism previously demonstrated in preclinical studies in animal models.
|
| ● |
Toxicity of PDS0101 remains limited to low-grade local injection site reactions.
|
| ● |
Earlier and greater proportion of ctDNA clearance with PDS0101 plus chemoradiation (CRT) vs. SOC CRT alone 81.3% clearance after 3 weeks vs. 30.3% with SOC (p=0.0018), and 91.7% of clearance at 5 weeks vs. 53.1% with SOC (p=0.0179).
|
| ● |
Baseline ctDNA levels correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node involvement; 100% of patients treated with PDS0101 had cancer that had spread to the lymph nodes.
|
| ● |
All patients received at least 2 doses of PDS0101.
|
| ● |
Median follow-up was 19 months.
|
| ● |
36-month overall survival (OS) rate was 84.4% among all patients, and 100% for the eight patients who received all five doses of PDS0101. Historical published data show 36-month OS rate with chemoradiation in
this population of approximately 64%.
|
| ● |
36-month progression free survival (PFS) rate was 74.9% among all patients and 100% for the eight patients who received all five doses of PDS0101. Historical published data show 36-month PFS rate with
chemoradiation in this population of approximately 61%.
|
| ● |
Complete metabolic response (CMR) was achieved in 15/17 (88%) patients.
|
| ● |
PDS0101 appeared to be safe and well-tolerated. The most common treatment-related toxicities were injection site reactions in 12/17 (71%) patients.
|
| ● |
75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months
|
| ● |
12-month survival rate in (ICI) resistant patients of 72%
|
| ● |
Median OS in ICI-resistant HPV-positive patients is approximately 20 months; published median OS is 3.4 months
|
| ● |
the timing and costs of our planned and ongoing clinical trials;
|
| ● |
the outcome, timing and costs of seeking regulatory approvals;
|
| ● |
the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;
|
| ● |
the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other
intellectual property rights; and
|
| ● |
the extent to which we license or acquire other products and technologies.
|
|
Three Months Ended
September 30,
|
Increase ( Decrease)
|
|||||||||||||||
|
2026
|
2025
|
$ Amount
|
%
|
|||||||||||||
|
(in thousands)
|
||||||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development expenses
|
$
|
2,051
|
$
|
4,576
|
$
|
(2,525
|
)
|
(55
|
)%
|
|||||||
|
General and administrative expenses
|
3,845
|
3,564
|
281
|
8
|
%
|
|||||||||||
|
Total operating expenses
|
5,896
|
8,140
|
(2,244
|
)
|
(28
|
)%
|
||||||||||
|
Loss from operations
|
(5,896
|
)
|
(8,140
|
)
|
2,244
|
(28
|
)%
|
|||||||||
|
Interest income (expense), net
|
(1,725
|
)
|
(869
|
)
|
(856
|
)
|
99
|
%
|
||||||||
|
Net loss and comprehensive loss
|
$
|
(7,621
|
)
|
$
|
(9,009
|
)
|
$
|
1,388
|
(15
|
)%
|
||||||
|
Nine Months Ended
September 30,
|
Increase (Decrease)
|
|||||||||||||||
|
2026
|
2025
|
$ Amount
|
%
|
|||||||||||||
|
(in thousands)
|
||||||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development expenses
|
$
|
8,774
|
$
|
14,620
|
$
|
(5,846
|
)
|
(40
|
)%
|
|||||||
|
General and administrative expenses
|
10,140
|
10,249
|
(109
|
)
|
(1
|
)%
|
||||||||||
|
Total operating expenses
|
18,914
|
24,869
|
(5,955
|
)
|
(24
|
)%
|
||||||||||
|
Loss from operations
|
(18,914
|
)
|
(24,869
|
)
|
5,955
|
(24
|
)%
|
|||||||||
|
Interest income (expense), net
|
(5,807
|
)
|
(3,233
|
)
|
(2,574
|
)
|
80
|
%
|
||||||||
|
Benefit from income taxes
|
-
|
1,170
|
(1,170
|
)
|
(100
|
)%
|
||||||||||
|
Net loss and comprehensive loss
|
$
|
(24,721
|
)
|
$
|
(26,932
|
)
|
$
|
2,211
|
(8
|
)%
|
||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Net cash used in operating activities
|
$
|
(15,388
|
)
|
$
|
(24,049
|
)
|
||
|
Net cash provided by financing activities
|
3,921
|
8,558
|
||||||
|
Net decrease in cash and cash equivalents
|
$
|
(11,467
|
)
|
$
|
(15,491
|
)
|
||
| ● |
the initiation, progress, timing, costs and results of our planned clinical trials;
|
| ● |
the effects of health epidemics, pandemics, or outbreaks of infectious diseases, on our business operations, financial condition, results of operations and cash flows;
|
| ● |
the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory
authorities;
|
| ● |
the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
|
| ● |
the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us now or in the future;
|
| ● |
the effect of competing technological and market developments;
|
| ● |
the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize our products on our own; and
|
| ● |
the initiation, progress, timing and results of our commercialization of our clinical and product candidates, if approved, for commercial sale.
|
| ITEM 3: |
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
|
| ITEM 4: |
CONTROLS AND PROCEDURES
|
| PART II. |
OTHER INFORMATION
|
| ITEM 1. |
LEGAL PROCEEDINGS
|
| ITEM 1A. |
RISK FACTORS
|
| ● |
the clinical data supporting PDS0301 in metastatic colorectal cancer is based on Phase 2 results, and future clinical trials, including the planned randomized Phase 2b trial, may not replicate or confirm
these results;
|
| ● |
we may not be successful in advancing PDS0301 through a randomized Phase 2b development program on the timeline or within the budget we anticipate;
|
| ● |
the reallocation of resources away from PDS0101 may result in a loss of value for our PDS0101 program if we are unable to secure a strategic partnership on favorable terms, or at all;
|
| ● |
we may have expended significant resources on the PDS0101 program, including the VERSATILE-003 trial, that will not result in any direct commercial benefit to us;
|
| ● |
our strategic refocus narrows the breadth of our clinical pipeline, which increases our dependence on the success of PDS0301;
|
| ● |
the discontinuation of the VERSATILE-003 trial may negatively affect our relationships with clinical trial investigators, trial participants, or collaborators; and
|
| ● |
our stockholders, potential investors, or potential partners may view the strategic refocus unfavorably, which could adversely affect the market price of our common stock and our ability to raise capital.
|
| ● |
set and obtain an acceptable price for PDS0301 or Versamune® products, and obtain coverage and adequate reimbursement from third-party payors;
|
| ● |
establish sales, marketing, manufacturing and distribution systems;
|
| ● |
add operational, financial and management information systems and personnel, including personnel to support our clinical, manufacturing and planned future clinical development and commercialization efforts
and operations as a public company;
|
| ● |
develop manufacturing capabilities for bulk materials and manufacture commercial quantities of PDS0301 or Versamune® products at acceptable cost levels;
|
| ● |
achieve broad market acceptance of PDS0301 and other Versamune® products, Versamune® in combination with PDS0301 or Infectimune® based-products in the medical community and with third-party payors and
consumers;
|
| ● |
attract and retain an experienced management and advisory team;
|
| ● |
launch commercial sales of PDS0301, Versamune® products, Versamune® in combination with PDS0301 and other oncology products, and Infectimune® based-products, whether alone or in collaboration with others; and
|
| ● |
maintain, expand and protect our intellectual property portfolio.
|
| ● |
we may not be able to demonstrate that PDS0301 is safe and effective to the satisfaction of the FDA;
|
| ● |
the FDA may not agree that the completed Phase 2 clinical trials of PDS0301 satisfy the FDA’s requirements and may require us to conduct additional testing;
|
| ● |
the results of our future clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;
|
| ● |
the FDA may disagree with the number, design, size, conduct or implementation of one or more of our clinical trials;
|
| ● |
the contract research organizations, or CROs, that we retain to conduct clinical trials may take actions outside of our control that materially and adversely impact our clinical trials;
|
| ● |
the FDA may not find the data from our preclinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of PDS0301 outweigh the safety risks;
|
| ● |
the FDA may disagree with our interpretation of data from our preclinical studies and clinical trials;
|
| ● |
the FDA may not accept data generated at our clinical trial sites;
|
| ● |
if our BLA is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our
application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;
|
| ● |
the FDA may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;
|
| ● |
the FDA may identify deficiencies in our manufacturing processes or facilities; or
|
| ● |
the FDA may change its approval policies or adopt new regulations.
|
| ● |
the initiation, progress, timing, costs and results of our planned clinical trials;
|
| ● |
the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;
|
| ● |
the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
|
| ● |
the cost of defending potential intellectual property disputes, including any patent infringement actions brought by third parties against us now or in the future;
|
| ● |
the effect of competing technological and market developments;
|
| ● |
the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize PDS0301 on our own; and
|
| ● |
the initiation, progress, timing and results of the commercialization of PDS0301, if approved, for commercial sale.
|
| ● |
develop and commercialize immunotherapies that are superior to other alternatives in the market;
|
| ● |
demonstrate through our clinical trials that PDS0301 is differentiated from existing and future therapies;
|
| ● |
attract qualified scientific, immunotherapy development and commercial personnel;
|
| ● |
obtain additional patent or other proprietary protection for PDS0301 or Versamune® and Infectimune®-based products;
|
| ● |
obtain required regulatory approvals;
|
| ● |
obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third-party payors; and
|
| ● |
successfully develop and commercialize, independently or with collaborators, new applications for PDS0301 or immunotherapies.
|
| ● |
regulatory authorities may withdraw their approval of PDS0301 or impose restrictions on its distribution or other risk management measures;
|
| ● |
regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;
|
| ● |
we may be required to change the way PDS0301 is administered or to conduct additional clinical trials;
|
| ● |
we could be sued and held liable for injuries sustained by patients;
|
| ● |
we could elect to discontinue the sale of PDS0301;
|
| ● |
our entire Versamune® and Infectimune®-based pipeline could be then put at risk; and
|
| ● |
our reputation may suffer.
|
| ● |
restrictions on manufacturing PDS0301;
|
| ● |
restrictions on the labeling or marketing of PDS0301;
|
| ● |
restrictions on distribution or use of PDS0301;
|
| ● |
requirements to conduct post-marketing studies or clinical trials;
|
| ● |
suspension of any of our ongoing clinical trials;
|
| ● |
warning letters;
|
| ● |
withdrawal of PDS0301 from the market;
|
| ● |
refusal to approve pending applications or supplements to approved applications that we submit;
|
| ● |
recalls of PDS0301;
|
| ● |
fines, restitution or disgorgement of profits or revenues;
|
| ● |
suspension or withdrawal of marketing approvals;
|
| ● |
refusal to permit the import or export of PDS0301;
|
| ● |
seizures of PDS0301; or
|
| ● |
injunctions or the imposition of civil or criminal penalties.
|
| ● |
the efficacy and potential advantages compared to alternative treatments;
|
| ● |
effectiveness of sales and marketing efforts;
|
| ● |
the cost of treatment in relation to alternative treatments;
|
| ● |
our ability to offer PDS0301 for sale at competitive prices;
|
| ● |
the convenience and ease of administration compared to alternative treatments;
|
| ● |
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
|
| ● |
the willingness of the medical community to offer customers PDS0301 in addition to or in the place of other immunotherapies;
|
| ● |
the strength of marketing and distribution support;
|
| ● |
the availability of third-party coverage and adequate reimbursement;
|
| ● |
whether the product is designated under physician and other provided treatment guidelines as a first, second, or third line therapy;
|
| ● |
the prevalence and severity of any side effects; and
|
| ● |
any restrictions on the use of PDS0301 together with other medications.
|
| ● |
decreased demand for PDS0301 or other immunotherapies that we may develop;
|
| ● |
injury to our reputation and significant negative media attention;
|
| ● |
withdrawal of clinical trial participants;
|
| ● |
significant costs to defend any related litigation;
|
| ● |
substantial monetary awards to trial subjects or patients;
|
| ● |
loss of revenue; and
|
| ● |
the inability to commercialize any products we may develop.
|
| ● |
different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries;
|
| ● |
reduced protection for intellectual property rights;
|
| ● |
unexpected changes in tariffs, trade barriers and regulatory requirements;
|
| ● |
economic weakness, including inflation, or political instability in particular foreign economies and markets;
|
| ● |
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
|
| ● |
foreign reimbursement, pricing and insurance regimes;
|
| ● |
foreign taxes;
|
| ● |
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
|
| ● |
workforce uncertainty in countries where labor unrest is more common than in the United States;
|
| ● |
potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions;
|
| ● |
shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
|
| ● |
business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.
|
| ● |
the possible failure of the third party to manufacture our product candidate according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products
over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
|
| ● |
the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us;
|
| ● |
the possible breach by the third-party contractors of our agreements with them;
|
| ● |
the failure of third-party contractors to comply with applicable regulatory requirements;
|
| ● |
the possible failure of the third party to manufacture our product candidates according to our specifications;
|
| ● |
the possible mislabeling of clinical supplies, potentially resulting in issues including the wrong dose amounts being supplied or active drug or placebo not being properly identified;
|
| ● |
the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner,
resulting in lost sales; and
|
| ● |
the possible misappropriation of our proprietary information, including our trade secrets and know-how.
|
| ● |
significant time and effort from our management team;
|
| ● |
financial funding to support said collaboration;
|
| ● |
coordination of our research and development programs with the research and development priorities of our collaborators; and
|
| ● |
effective allocation of our resources to multiple projects.
|
| ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
| ITEM 3. |
DEFAULTS UPON SENIOR SECURITIES
|
| ITEM 4. |
MINE SAFETY DISCLOSURES
|
| ITEM 5. |
OTHER INFORMATION
|
| ITEM 6. |
EXHIBITS
|
|
Exhibit
Number
|
Exhibit Description
|
|
|
3.1
|
Amendment to the Eighth Amended and Restated Certificate of Incorporation, as amended. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed August 14, 2026 and incorporated be reference
herein).
|
|
|
4.1
|
Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on September 8, 2026, and incorporated by reference herein)
|
|
|
4.2
|
Form of Common Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on September 8, 2026, and incorporated by reference herein)
|
|
|
10.1
|
Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 8, 2026, and incorporated by reference herein)
|
|
|
10.2
|
Form of Registration Rights Agreement (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 8, 2026, and incorporated by reference herein)
|
|
|
10.3
|
Form of Option Agreement (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on September 8, 2026, and incorporated by reference herein)
|
|
|
31.1*
|
Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002.
|
|
|
32.1 *
|
Certification of Principal Executive and Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
|
|
|
101.INS*
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
|
|
|
101.SCH*
|
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.
|
|
|
101.CAL*
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
|
| * |
Filed herewith (unless otherwise noted as being furnished herewith)
|
| + |
Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request.
|
|
PDS Biotechnology Corporation
|
||
|
November 13, 2026
|
By:
|
/s/ Frank Bedu-Addo
|
|
Frank Bedu-Addo, Ph.D.
|
||
|
President and Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)
|
||
|
November 13, 2026
|
By:
|
/s/ Janetta Trochimiuk
|
|
Janetta Trochimiuk
|
||
|
Controller
|
||
|
(Principal Accounting Officer)
|
||